Singular Research upgraded shares of Quantum Biopharma (CVE:QNT – Free Report) to a moderate buy rating in a research note published on Wednesday morning,Zacks.com reports.
Quantum Biopharma Price Performance
Insider Transactions at Quantum Biopharma
In related news, Senior Officer Nathan Patrick Coyle sold 3,000 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of C$20.16, for a total transaction of C$60,480.00.
Featured Stories
- Five stocks we like better than Quantum Biopharma
- Transportation Stocks Investing
- These 3 Consumer Staple Giants Are Oversold and Set to Skyrocket
- What does consumer price index measure?
- MarketBeat Week in Review – 06/16 – 06/20
- Overbought Stocks Explained: Should You Trade Them?
- New All-Time Highs Coming for Broadcom? Wall Street Says Yes
Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
